evaluation of primary haemostasis with platelet function analyser pfa-10

Clicks: 71
ID: 154883
2004
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Popular

Ranked #195 of 231 articles by views in planta medica

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 231 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Abstract

Background. Laboratory evaluation is indicated when a disorder of primary haemostasis is suspected by a personal or family history of easy bruising, nose bleeds, menorrhagia or postoperative bleeding, especially following dental extraction or tonsillectomy. The traditional procedures to diagnose defect in primary haemostasis are bleeding time, measurement of von Willebrand factor and platelet aggregometry. The most widely used screening test is bleeding time. Despite attempts at standardisation, the bleeding time remains poorly reproducible and is relatively insensitive to platelet function defects. Recently, a new test method, the platelet function analyser (PFA-100) has been introduced for the investigation of primary haemostasis. PFA-100 measures the ability of platelets activated in a high-shear environment to occlude an aperture in membrane treated with collagen and epinephrine and/or collagen and ADP. The time taken for flow across the membrane to stop (closure time) is recorded.

Conclusions. This article highlights the benefits and limitations of the clinical utility of the PFA-100. Because of its simplicity and excellent sensitivity the PFA-100 is useful mainly as a screening test for von Willebrand disease, hereditary and acquired platelet-dysfunctions including acetylsalicylic acidinduced abnormalities. Recently the PFA-100 has been shown to be of value in monitoring antiplatelet therapy and in monitoring desmopressin treatment in von Willebrand disease.

Reference Key
mlakar2004zdravnikievaluation Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors ;Uroš Mlakar;Irena Preložnik Zupan;Rika Strauch
Journal planta medica
Year 2004
DOI
DOI not found
URL
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.